Project Grant R01HL180913
Award Date 9/15/25
Completion Date 8/31/29
Dollars Obligated $769K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Missouri, USA
Similar Awards
- The National Heart, Lung, and Blood Institute (NHLBI), under CFDA Program 93.837 Cardiovascular Diseases Research, awarded a $776,791 Project Grant to The Washington University to study the impact of sequence changes on key intrinsically disordered regions of cardiac troponin. This research aims to elucidate how mutations and post-translational modifications affecting disordered regions of the troponin complex can disrupt cardiac muscle contraction regulation, leading to diseases like...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $425,505 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Louisiana State University Health Sciences Center-Shreveport (LSU Health Sciences Center-Shreveport) to investigate the role of cell-specific Programmed Death-Ligand 1 (PD-L1) in cardiac pathophysiology following ischemic injury and cancer. The project aims to elucidate the specific mechanisms by which fibroblast-specific and myeloid...
- The University of Washington received a $663,578 Project Grant award from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837). The award, effective August 15, 2025 through May 31, 2029, supports research to better diagnose and understand cardiac sarcoidosis, a form of inflammatory cardiomyopathy. The project aims to "perform 'deep phenotyping' with genetic testing, PET imaging, metabolomic studies, and voltage-guided endomyocardial...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is for a targeted approach to treat immunotherapy-induced myocarditis (inflammation of the heart) using CXCR3 blockade. The total funding amount is $773,843, awarded on September 19, 2025, with an ultimate completion date of May 31, 2029. The key products and services to be delivered under this grant include: Validating the role of CXCR3-positive CD8+ T cells and...
- The National Heart Lung and Blood Institute (NHLBI) awarded a $711,039 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Research Institute at Nationwide Children's Hospital. The award supports research to determine the functions of the cardiac m6A methyltransferases METTL3 and METTL14 in early myocardial development, and whether their dysregulation contributes to the pathogenesis of fetal dilated cardiomyopathy (DCM). The proposed study leverages mouse...
- This federal Project Grant award of $552,318 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to investigate the role of carbonic anhydrase as a cardioprotective target for mitigating the cardiotoxic effects of anthracycline chemotherapy drugs like doxorubicin. The research leverages human-induced pluripotent stem cell-derived cardiomyocytes to model anthracycline-induced cardiotoxicity and uses CRISPR interference/activation...
- This federal Project Grant award of $680,583.00 from the National Heart Lung and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) supports research to discover genetic modifiers and novel therapies for anthracycline-induced cardiotoxicity. The study aims to use zebrafish models to test candidate genes identified from human genome-wide association studies, as well as explore the role of aging-associated epicardial remodeling in cardiotoxicity. Key areas of focus include...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) is focused on conducting definitive (GLP) toxicity and toxicology studies for a novel small molecule therapy to protect against cardiotoxicity in triple negative breast cancer (TNBC) patients. The $1,000,000 award will support the development and commercialization of this novel, safe, and effective therapy that synergizes with anthracyclines, such...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $161,903 Project Grant to The Leland Stanford Junior University (Stanford University) on January 31, 2025 under the Cardiovascular Diseases Research (CFDA 93.837) program. The project aims to investigate risk stratification and outcomes across the spectrum of immune checkpoint inhibitor (ICI) cardiotoxicity subtypes. Specifically, the study will: (1) retrospectively examine cardiac and oncologic outcomes associated with ICI...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $402,911 Project Grant to The Trustees of Columbia University in the City of New York to develop a pericardial mRNA therapy for the treatment of myocardial infarction (heart attack). The research aims to create a new anti-inflammatory drug based on previous studies of stem cell derivatives for heart repair, which will be administered via minimally invasive...